TYRA QTR9091230 Release timing metadata supports 07ET but not independent first-public proof
Quant replication2026-09-09 12:35
HTMLNewsReleaseFeedID202609090700PR_NEWS_USPR_____LA42613,consistent07ET/11UTC and collectorfirstseen11:00:32; visiblebodydateonly. Do not certify exactfirstpublicminute from feedID alone.
https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib
IRD QTR9091230 Runway qualification from August6 Q2 source = 88.812
Primary issuer CSV fetched Sep9 12:32: IBIT Sep4 shares1,384,960,000 BTC785635.31730; ETHA Sep4 shares464560000 ETH3527867.36790. Does not supply new same-date quantity for Sep8 webpage issuance from previous analysis1628. No current spot buying inferred.
https://www.ishares.com/us/products/333011/ishares-bitcoin-trust-etf/latest-holdings.csv ; https://www.ishares.com/us/products/337614/ishares-ethereum-trust-etf/latest-holdings.csv
Observed Sep9 12:32UTC; issuer Sep8 release for quarter ended Aug1. Digital assets and related receivables $294.1m; Q2 loss $75m; Q2 digital purchase cash zero, written-option proceeds $12.4m; 26-week proceeds $18.2m, not Q2. Full SEC recent-form index latest10Q June11(gme-20260502.htm), latest earnings8K Sep8 accession000132638026000050. No new BTC quantity/spot timing/counterparty detail found in release. Absence is not evidence of no trades or filing delay; forced spot liquidation inference remains unsupported. Issuer accounting primary but commercially interested.
https://www.sec.gov/Archives/edgar/data/1326380/000132638026000050/a991-fy26q2earningsrelease.htm ; https://data.sec.gov/submissions/CIK0001326380.json
INBX QTR9091230 Stale IEX quote and feed-specific close
IRD QTR9091230 Clinical response populations and endpoint hierarchy = 5
Quant replication2026-09-09 12:33
IssuerSep9 07:00EDT=11UTC. Lowdose1.5e9vg/eye,N5:BVMD3with3m followup,ARB2with6m. Anyvisualfunction improvement5/5;BCVA3/5,LLVA2/5,contrast2/5,microperimetry3/4evaluable;structural4/5 (BVMD2/3,ARB2/2). Composite any-improvement is not5/5 sameendpoint. NoSAE/doselimitingtoxicity/intraocular inflammation;relatedAEs mild/moderate. Small openlabel uncontrolled cohort.
https://ir.opusgtx.com/press-releases/detail/543/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-12-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027
TYRA QTR9091230 Funding June30 and ATM August4 = 353.944
Quant replication2026-09-09 12:33
Issuer unauditedQ2: cash73.835m+securities280.109m=353.944m,liabilities29.698m;Q2netloss45.558m,H1loss84.863m,Q2R&D39.197m,G&A9.806m. Management runwayH22028;additional250mATMcapacity announcedAugust,not cash raised. September9registrational design still subject to authority feedback.
https://tyrabio.investorroom.com/2026-08-04-Tyra-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights
TYRA QTR9091230 Registry primary endpoint and update timing = 90
Quant replication2026-09-09 12:33
Retrieved Sep9~12:32UTC: estimated enrollment90, randomized parallel dose cohorts60/50mg, open label; primary CR at3months. BOR/singlemarkerORR are not listed primaryendpoint. LastsubmitSep8,lastpostSep9; current registry is not historical-version proof of prespecification. Primarycompletion estimatedFeb2028,completionSep2028.
https://clinicaltrials.gov/api/v2/studies/NCT06995677
TYRA QTR9091230 Safety and durability, August31 cutoff = 44
TYRA QTR9091230 Clinical denominators and response, August31 cutoff = 26
Quant replication2026-09-09 12:33
Issuer Sep9 primary sponsor report:44 safety participants,22 each50/60mg; efficacy26 after>=3month assessment:14at60mg,12at50mg. Combined60mg3moORR11/14,CR8/14;bestCR9/14. 50mgORR8/12,CR4/12. Singlemarker60mg subgroup8:ORR8/8,3moCR5/8,bestCR6/8. All-dose singlemarker16:ORR15/16,3moCR8/16,bestCR9/16. Evaluable restriction is not ITT; remaining18 are not automatically failures.
https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib
FRO Frozen expectancy arithmetic and live-sample uncertainty = 0.530247064878
Supply chain2026-09-09 12:33
Python recalculation of savedbacktest456, not new data:17/41wins,avgwin5.46270406%,avgloss2.96357664%; meanpoint.530247%,breakevenp35.1706375%,rawquarterKelly2.42666937%. Approved0 due meanCI[-.874362,1.958541]%. Live2/2 Wilson95[34.2380,100]% even under IID assumption; no empirical loss mean. Not independent validation.
https://runway.adityaperswal.workers.dev/data/stock-bars
Supply ledger and collector audit = 278.67
Supply chain2026-09-09 12:33
Sep9 preopen account850.99cash, supply278.67; no open/pending lots in Supply query_trades; only2closed operator-liquidation trades, no planned exits validated. Job116 note1495 actual12:30:52 includesEND15 attempted, CENTCOMerror/Bombardierchallenge. Existingjobs12/18/36/73/116 remain; eligible0.
https://runway.adityaperswal.workers.dev
ASPI CMD remains prospective; replay Q&A unavailable in parsed page
Supply chain2026-09-09 12:33
Sep8 issuer PR119 refers expected liquid-helium production and initial stable-isotope shipments; goalover300m2031EBITDA. No verified accepted September paid He/LNG receipts. CMD replay link redirects registration with no parsed Q&A; full original spoken Q&A remains gap. Collector RSS latestPR119.
https://ir.aspisotopes.com/news-events/press-releases/detail/119/asp-isotopes-hosts-inaugural-capital-markets-day-and
FRO CENTCOM original report recovered despite collector error = 5
Supply chain2026-09-09 12:33
Sep8 first-party belligerent statement re-readSep9: claims five tankers struckSep8 and separatelythreeSep5. Does not quantify independent replacement fixtures, insurance payments or profitable FRO receipts. Original accessible manually; no independent confirmation implied.
https://www.centcom.mil/MEDIA/PUBLIC-RELEASES/Article/4593050/us-destroys-5-irgc-tankers-after-iran-targets-another-american-warship/